Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma
Explore this paper's citation graph
- Type
- article
- Published
- 2017-07-01
- Cited by
- 0
- References
- 0
- OpenAlex
- https://openalex.org/W2739990886
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:80137634
Keywords
Cetuximab, Head and neck squamous-cell carcinoma, Medicine, Cancer research, Epidermal growth factor receptor
References
No references recorded for this paper.
Cited by
No citing papers recorded for this paper.
Related papers
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC)
- Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
- Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc
- The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
- Should cetuximab replace cisplatin in head and neck cancer?
- Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
- Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma